Global Smart Cards Market to Grow at CAGR 8.84 % Key to Overall Growth: Global Market Analysis and Opportunity Assessment, 2017-2021

Smart Cards market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

Smart cards are pocket-sized plastic cards embedded with integrated circuits (ICs) and are also known as microchips. These are primarily used for security purposes such as authentication and identification. Smart cards are also used for data storage and application processing.

Smart cards are broadly classified into contact-based and contactless cards. Contact-based smart cards have a contact area of approximately 1 square cm and are used by inserting them into a smart card reader. On the other hand, contactless smart cards function with the help of radio frequency, which eliminates the need for any physical insertion into the card reader.

Get a free sample of Smart Cards market report @ https://www.360marketupdates.com/enquiry/request-sample/11005681

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Smart Cards market projected to grow at a CAGR of 8.84% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: – Availability of hybrid smart cards

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005681

Market Segmentation: –

  • By technology: –
  • Contact-based smart cards
  • Contactless smart cards
  • By end-user
  • Telecom
  • Government
  • BFSI
  • Transportation

Geographic Segmentation: –

  • APAC
  • Europe
  • South America
  • North America
  • MEA

To calculate the Smart Cards market size the report considers the revenues generated from the sale and shipment of contact-based and contactless smart cards. The report covers the market landscape and its growth prospects over the coming years.

Further it converses about key vendors operating in Smart Cards market like Gemalto, Giesecke & Devrient, OT-Morpho, Watchdata, ARM, Rambus, CardLogix, DataCard, HID Global, Infineon Technologies, NXP Semiconductors, and Smart Card IT Solutions.

Some of the Exhibits included in Smart Cards Market report: –

Exhibit 01: Factors affecting market revenue

Exhibit 02: Exhibit 03: Product lifecycle

Exhibit 04: Global smart cards market 2016-2021 ($ billions)

Exhibit 05: Global smart cards market by shipment 2016-2021 (million units)

Exhibit 06: Global smart cards market by technology 2016 (% share of revenue)

Exhibit 07: Global smart cards market by technology 2016 (% share of shipment)

Exhibit 08: Global smart cards market by technology 2016-2021 (% share of revenue)

Exhibit 09: Global smart cards market by technology 2016-2021 (% share of shipment)

Exhibit 10: Global smart cards market by contact-based smart cards 2016-2021 ($ billions)

Exhibit 11: Global smart cards market by contact-based smart cards 2016-2021 (billion units)

Exhibit 12: Global smart cards market by contactless smart cards 2016-2021 ($ billions)

Exhibit 13: Global smart cards market by contactless smart cards 2016-2021 (billion units)

Purchase Smart Cards market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005681

With geographic breakdown of the market in terms of detailed analysis and impact, Smart Cards market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.

Global Epigenetics Market to Grow at CAGR 13.22 %: In-Depth Market Analysis with Inputs from Industry Experts

Epigenetics market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

Epigenetics is a biological process to control gene expression by altering the chromatin structure. Genes which are going to be expressed are associated with accessible chromatin regions, whereas silent genes are often associated with inaccessible chromatin regions. Epigenetics products that include reagents, kits, enzymes, instruments, and drugs help in analyzing epigenetic changes on the basis of which epigenetic therapy develops.

Get a free sample of Epigenetics market report @ https://www.360marketupdates.com/enquiry/request-sample/11005692

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Epigenetics market projected to grow at a CAGR of 13.22% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: –

  • Increasing use of epigenetics as a tool to understand development and disease
  • Increasing demand for personalized medicine
  • Rise in investment in R&D

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005692

Market Segmentation: –

  • Global epigenetics market by reagents
  • Global epigenetics market by kits
  • Global epigenetics market by others

Geographic Segmentation: –

  • Epigenetics market in Americas
  • Epigenetics market in EMEA
  • Epigenetics market in APAC

To calculate the Epigenetics market size the report considers the revenue generated from the retail sales of epigenetics products. The report covers the market landscape and its growth prospects over the coming years.

Further it converses about key vendors operating in Epigenetics market like Abcam, Bio-Rad Laboratories, Merck, Thermo Fisher Scientific, Active Motif, BellBrook Labs, BioVision, CELGENE, Cisbio.com, Diagenode, Epizyme, Illumina, New England Biolabs, Novartis, and QIAGEN.

Some of the Exhibits included in Epigenetics Market report: –

Exhibit 01: Epigenetic changes in DNA

Exhibit 02: Normal cellular functions regulated by epigenetic mechanisms and molecular abnormalities caused by epigenetic errors

Exhibit 03: Global epigenetics market:

Exhibit 04: Global epigenetics market 2016-2021 ($ billions)

Exhibit 05: Factors impacting global epigenetics market

Exhibit 06: Five forces analysis

Exhibit 07: Global epigenetics market by product 2016-2021 (% share)

Exhibit 08: Global epigenetics market by product: Snapshot

Exhibit 09: Global epigenetics market by reagents 2016-2021 ($ billions)

Exhibit 10: Global epigenetic market by kits 2016-2021 ($ billions)

Exhibit 11: Global epigenetic market by others 2016-2021 ($ billions)

Exhibit 12: Global epigenetics market by geography 2016-2021 (% share)

Exhibit 13: Global epigenetics market by geography: Snapshot

Purchase Epigenetics market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005692

With geographic breakdown of the market in terms of detailed analysis and impact, Epigenetics market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.

Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology

KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsKYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting

THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (carfilzomib) administered at 56 mg/m2 twice weekly and dexamethasone (Kd56) reduced the risk of death by 21 percent over Velcade® (bortezomib) and dexamethasone (Vd), resulting in a 7.6 month OS benefit (median OS 47.6 months for Kd56 versus 40.0 for Vd, HR=0.79; p=0.01). The OS benefit was consistent regardless of prior Velcade therapy (HR=0.75 for no prior Velcade; HR=0.84 for prior Velcade). This Kd56 regimen is already approved in the U.S., European Union and other countries based on the primary analysis of progression-free survival (PFS) in the ENDEAVOR study.

“These results showed KYPROLIS and dexamethasone significantly reduced the risk of death compared to Velcade and dexamethasone in patients with relapsed or refractory multiple myeloma,” said study co-author and investigator Meletios A. Dimopoulos, M.D., professor of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine. “These results support the use of KYPROLIS and dexamethasone as a standard of care for multiple myeloma patients at first relapse.”

“In recent years, few clinical trials have demonstrated overall survival benefits in patients with relapsed or refractory multiple myeloma,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “In ENDEAVOR, the only head-to-head trial comparing proteasome inhibitors, KYPROLIS showed a statistically significant overall survival benefit of 7.6 months over Velcade. These results published today in The Lancet Oncology support KYPROLIS as a superior proteasome inhibitor in relapsed multiple myeloma patients. We’ve shared these data with regulatory agencies in the U.S. and Europe to support a potential label update.”

Adverse events observed in this updated analysis were consistent with those previously reported for ENDEAVOR. Notably, rates of grade 2 or higher peripheral neuropathy, a frequent dose-limiting toxicity of Velcade, were five-times lower in patients receiving Kd56 versus patients receiving Vd (7 percent versus 35 percent, respectively). The most common adverse events (greater than or equal to 20 percent) in the KYPROLIS arm were anemia, diarrhea, pyrexia, dyspnea, fatigue, hypertension, cough, insomnia, upper respiratory tract infection, peripheral edema, nausea, bronchitis, asthenia, back pain, thrombocytopenia and headache.

As previously published in The Lancet Oncology, patients treated with Kd56 also achieved PFS of 18.7 months compared to 9.4 months in those receiving Vd, meeting the primary endpoint of the study (HR=0.53; 95 percent CI: 0.44 – 0.65; p<0.0001).

Since its approval in 2012, KYPROLIS has been prescribed to over 50,000 patients worldwide. The KYPROLIS clinical program continues to focus on providing solutions for physicians and patients in treating this frequently relapsing and difficult-to-treat cancer. KYPROLIS is available for patients whose myeloma has relapsed or become resistant to another treatment and continues to be studied in a range of combinations and patient populations.

About ENDEAVOR
The randomized ENDEAVOR (RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma) trial of 929 patients evaluated Kd56 versus Vd in patients whose multiple myeloma has relapsed after at least one, but not more than three, prior therapeutic regimens. The primary endpoint of the trial was PFS, defined as the time from treatment initiation to disease progression or death. The primary analysis was published in The Lancet Oncology and is described in the Prescribing Information.

Patients received treatment until progression with KYPROLIS as a 30-minute infusion on days 1, 2, 8, 9, 15 and 16 of 28 day treatment cycles, along with low-dose dexamethasone (20 mg). For Cycle 1 only, KYPROLIS was administered at 20 mg/m2 on days 1 and 2, and if tolerated was escalated to 56 mg/m2 from day 8 Cycle 1 onwards. Patients who received bortezomib (1.3 mg/m2) with low-dose dexamethasone (20 mg) were treated with bortezomib administered subcutaneously or intravenously at the discretion of the investigator and in accordance with regional regulatory approval of bortezomib. More than 75 percent of the patients in the control arm received bortezomib subcutaneously. This study was conducted at 235 sites worldwide.

For information about this trial, please visit www.clinicaltrials.gov under trial identification number NCT01568866 or the News Release section of Amgen.com.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer, characterized by a recurring pattern of remission and relapse.1 It is a rare and very aggressive disease that accounts for approximately one percent of all cancers.2,3 In the U.S., there are nearly 95,000 people living with, or in remission from, multiple myeloma.4 Approximately 30,330 Americans are diagnosed with multiple myeloma each year and 12,650 patient deaths are reported on an annual basis.4

About KYPROLIS® (carfilzomib) 
Proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or no longer needed.5 KYPROLIS has been shown to block proteasomes, leading to an excessive build-up of proteins within cells.5 In some cells, KYPROLIS can cause cell death, especially in myeloma cells because they are more likely to contain a higher amount of abnormal proteins.5,6

KYPROLIS is approved in the U.S. for the following:

  • In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

KYPROLIS is also approved in Argentina, Australia, Bahrain, Canada, Hong Kong, Israel, Japan, Kuwait, Lebanon, Macao, Mexico, Thailand, Colombia, S. Korea, Canada, Qatar, Switzerland, United Arab Emirates, Turkey, Russia, Brazil, India, Oman and the European Union. Additional regulatory applications for KYPROLIS are underway and have been submitted to health authorities worldwide.

IMPORTANT SAFETY INFORMATION

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of KYPROLIS administration.
  • Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart KYPROLIS at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure.
  • Patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with KYPROLIS and remain under close follow-up.

Acute Renal Failure

  • Cases of acute renal failure and renal insufficiency adverse events (including renal failure) have occurred in patients receiving KYPROLIS. Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS monotherapy. Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Reduce or withhold dose as appropriate.

Tumor Lysis Syndrome

  • Cases of Tumor Lysis Syndrome (TLS), including fatal outcomes, have occurred in patients receiving KYPROLIS. Patients with multiple myeloma and a high tumor burden should be considered at greater risk for TLS. Adequate hydration is required prior to each dose in Cycle 1, and in subsequent cycles as needed. Consider uric acid lowering drugs in patients at risk for TLS. Monitor for evidence of TLS during treatment and manage promptly. Withhold KYPROLIS until TLS is resolved.

Pulmonary Toxicity

  • Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in patients receiving KYPROLIS. Some events have been fatal. In the event of drug-induced pulmonary toxicity, discontinue KYPROLIS.

Pulmonary Hypertension

  • Pulmonary arterial hypertension (PAH) was reported in patients treated with KYPROLIS. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS for PAH until resolved or returned to baseline and consider whether to restart KYPROLIS based on a benefit/risk assessment.

Dyspnea

  • Dyspnea was reported in patients treated with KYPROLIS. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop KYPROLIS for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart KYPROLIS based on a benefit/risk assessment.

Hypertension

  • Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with KYPROLIS. Some of these events have been fatal. Monitor blood pressure regularly in all patients. If hypertension cannot be adequately controlled, withhold KYPROLIS and evaluate. Consider whether to restart KYPROLIS based on a benefit/risk assessment.

Venous Thrombosis

  • Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with KYPROLIS. Thromboprophylaxis is recommended for patients being treated with the combination of KYPROLIS with dexamethasone or with lenalidomide plus dexamethasone. The thromboprophylaxis regimen should be based on an assessment of the patient’s underlying risks.
  • Patients using oral contraceptives or a hormonal method of contraception associated with a risk of thrombosis should consider an alternative method of effective contraception during treatment with KYPROLIS in combination with dexamethasone or lenalidomide plus dexamethasone.

Infusion Reactions

  • Infusion reactions, including life-threatening reactions, have occurred in patients receiving KYPROLIS.

Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following or up to 24 hours after administration of KYPROLIS. Premedicate with dexamethasone to reduce the incidence and severity of infusion reactions. Inform patients of the risk and of symptoms of an infusion reaction and to contact a physician immediately if they occur.

Hemorrhage

  • Fatal or serious cases of hemorrhage have been reported in patients receiving KYPROLIS. Hemorrhagic events have included gastrointestinal, pulmonary, and intracranial hemorrhage and epistaxis. Promptly evaluate signs and symptoms of blood loss. Reduce or withhold dose as appropriate.

Thrombocytopenia

  • KYPROLIS causes thrombocytopenia with recovery to baseline platelet count usually by the start of the next cycle. Thrombocytopenia was reported in patients receiving KYPROLIS. Monitor platelet counts frequently during treatment with KYPROLIS. Reduce or withhold dose as appropriate.

Hepatic Toxicity and Hepatic Failure

  • Cases of hepatic failure, including fatal cases, have been reported during treatment with KYPROLIS. KYPROLIS can cause increased serum transaminases. Monitor liver enzymes regularly regardless of baseline values. Reduce or withhold dose as appropriate.

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal outcome have occurred in patients receiving KYPROLIS. Monitor for signs and symptoms of TTP/HUS. Discontinue KYPROLIS if diagnosis is suspected. If the diagnosis of TTP/HUS is excluded, KYPROLIS may be restarted. The safety of reinitiating KYPROLIS therapy in patients previously experiencing TTP/HUS is not known.

Posterior Reversible Encephalopathy Syndrome (PRES)

  • Cases of PRES have occurred in patients receiving KYPROLIS. PRES was formerly known as Reversible Posterior Leukoencephalopathy Syndrome. Consider a neuro-radiological imaging (MRI) for onset of visual or neurological symptoms. Discontinue KYPROLIS if PRES is suspected and evaluate. The safety of reinitiating KYPROLIS therapy in patients previously experiencing PRES is not known.

Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplantineligible Patients

  • In a clinical trial of transplant‐ineligible patients with newly diagnosed multiple myeloma comparing KYPROLIS, melphalan, and prednisone (KMP) vs bortezomib, melphalan, and prednisone (VMP), a higher incidence of serious and fatal adverse events was observed in patients in the KMP arm. KYPROLIS in combination with melphalan and prednisone is not indicated for transplant‐ineligible patients with newly diagnosed multiple myeloma.

Embryo-fetal Toxicity

  • KYPROLIS can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals.
  • Females of reproductive potential should be advised to avoid becoming pregnant while being treated with KYPROLIS. Males of reproductive potential should be advised to avoid fathering a child while being treated with KYPROLIS. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus.

ADVERSE REACTIONS

  • The most common adverse reactions occurring in at least 20% of patients treated with KYPROLIS in the combination therapy trials: anemia, neutropenia, diarrhea, dyspnea, fatigue, thrombocytopenia, pyrexia, insomnia, muscle spasm, cough, upper respiratory tract infection, hypokalemia.
  • The most common adverse reactions occurring in at least 20% of patients treated with KYPROLIS in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.

Please see full prescribing information at www.kyprolis.com.

About Amgen’s Commitment to Oncology
Amgen Oncology is committed to helping patients take on some of the toughest cancers, such as those that have been resistant to drugs, those that progress rapidly through the body and those where limited treatment options exist. Amgen’s supportive care treatments help patients combat certain side effects of strong chemotherapy, and our targeted medicines and immunotherapies focus on more than a dozen different malignancies, ranging from blood cancers to solid tumors. With decades of experience providing therapies for cancer patients, Amgen continues to grow its portfolio of innovative and biosimilar oncology medicines.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements 
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (Media)
Kristen Neese, 805-313-8267 (Media)
Arvind Sood, 805-447-1060 (Investors)

References

  1. Jakubowiak A. Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives. Seminars in Hematology. 2012; 49(3)(1),S16-S32.
  2. GLOBOCAN 2012. Global Prevalence and Incidence. Available at: http://globocan.iarc.fr/old/summary_table_pop_prev.asp?selection=224900&title=World&sex=0&window=1&sort=0&submit=%C2%A0Execute%C2%A0. Accessed on January 6, 2017.
  3. American Cancer Society. Multiple myeloma. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003121-pdf.pdf. Accessed on January 6, 2017.
  4. National Cancer Institute. SEER Stat Fact Sheets: Myeloma. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed on January 6, 2017.
  5. Moreau P, Richardson PG, Cavo M, et al. Proteasome Inhibitors in Multiple Myeloma: 10 Years Later. Blood. 2012; 120(5):947-959.
  6. Kortuem KM and Stewart AK. Carfilzomib. Blood. 2012; 121(6):893-897.

View original content:http://www.prnewswire.com/news-releases/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-endeavor-trial-published-in-the-lancet-oncology-300508874.html

SOURCE Amgen

Global Emergency Shutdown Valves Market to Grow at CAGR 3.51 %: Present Scenario, Market Landscape and The Growth Prospects Analysis and Forecast 2017-2021

Emergency Shutdown Valves market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

Emergency shutdown system (ESD system) is a safety instrument system that helps in protecting the industrial facilities from any accidents or emergency situations. Oil and gas, chemical and petrochemical, power, water and wastewater are some of the major end-users of this safety instrument system. This system recognizes the threat and takes necessary measure to prevent any catastrophic events.

Emergency shutdown systems consist of emergency shutdown valves, sensors, PLC (Programmable logic controller) and other control devices. These components help in checking the conditions of each of the machinery and process to determine any problems or emergencies and this information is used by the control devices like PLC, DCS (Distributed control system) to take necessary action. The demand for these emergency shutdown systems have increased due to the raising industrial accidents and many of the end-user industries are implementing these systems to address the increasing concern over workplace safety. Growing awareness among the end-user industries is another reason for the implementation of emergency shutdown systems.

Get a free sample of Emergency Shutdown Valves market report @ https://www.360marketupdates.com/enquiry/request-sample/11005691

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Emergency Shutdown Valves market projected to grow at a CAGR of 3.51% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: –

  • Increasing use of remote shutdown valves
  • Increasing use of actuators in emergency shutdown valves
  • Implementation of emergency shutdown systems among end-user industries due to growing awareness

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005691

Market Segmentation: –

  • By end-user: –
  • Global emergency shutdown valves market in oil and gas industry
  • Global emergency shutdown valves market in chemical and petrochemical industry
  • Global emergency shutdown valves market in power industry
  • Global emergency shutdown valves market in pharmaceutical industry
  • Global emergency shutdown valves market in water and wastewater industry
  • Global emergency shutdown valves market in others

Geographic Segmentation: –

  • Emergency shutdown valves market in EMEA
  • Emergency shutdown valves market in APAC
  • Emergency shutdown valves market in Americas

To calculate the Emergency Shutdown Valves market size the report considers the new installations , sales and replacement and services market. The report covers the market landscape and its growth prospects over the coming years.

Further it converses about key vendors operating in Emergency Shutdown Valves market like Cameron, Emerson, Flowserve, General Electric, Metso, J Flow Controls, Rico, Winn-Marion, Pekos valves, MIR VALVE, PFF, Accord, DERVOS VALVES, AMOT, and MOGAS.

Some of the Exhibits included in Emergency Shutdown Valves Market report: –

Exhibit 01: Market landscape

Exhibit 02: Global emergency shutdown valve market 2016-2021 ($ millions)

Exhibit 03: Five forces analysis

Exhibit 04: Market overview by end-user segmentation 2016 and 2021 (% share)

Exhibit 05: End-user preference by safety integrity level

Exhibit 06: Safety integrity conformity and measurements

Exhibit 07: Global emergency shutdown valves market in oil and gas industry 2016-2021  ($ millions)

Exhibit 08: Performance of global emergency shutdown valves market in oil and gas industry

Exhibit 09: Global emergency shutdown valves market in chemical and petrochemical industry 2016-2021 ($ millions)

Exhibit 10: Performance of global emergency shutdown valves market in chemical and petrochemical industry

Exhibit 11: Global emergency shutdown valves market in power industry 2016-2021 ($ millions)

Exhibit 12: Performance of global emergency shutdown valves market in power industry

Exhibit 13: Global emergency shutdown valves market in pharmaceutical industry 2016-2021 ($ millions)

Purchase Emergency Shutdown Valves market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005691

With geographic breakdown of the market in terms of detailed analysis and impact, Emergency Shutdown Valves market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.

Huge Demand on Global Gate Bipolar Transistors (IGBT) STATCOM Market Present Scenario and Growth Prospects 2017-2022

“Global Gate Bipolar Transistors (IGBT) STATCOM Market Research Report 2017”, Purchase This Report by calling ResearchnReports.com at +1-888-631-6977.

The report, titled “Global Gate Bipolar Transistors (IGBT) STATCOM Market Report 2017-2022,” offers an in-depth and wide-ranging overview of this Industry to all users looking to expand their business profiles in any aspect. The report establishes a solid foundation for all users looking to enter the global market in terms of Industry inclinations, opportunities, hindrances, and competitive landscape analysis.

With the widespread Industry data concerning the noteworthy elements and segment of the Global Gate Bipolar Transistors (IGBT) STATCOM Market that can affect the growth predictions of the market, the report makes for a highly informative document. The report can proficiently help businesses and decision-makers in addressing these challenges intentionally to gain the determined benefits in the highly competitive Industry.

Get PDF Sample of Gate Bipolar Transistors (IGBT) STATCOM Market Report@

https://www.researchnreports.com/request_sample.php?id=144101

It clarifies a thorough synopsis of Global Gate Bipolar Transistors (IGBT) STATCOM market dependent on the central parameters. End users, merchandises, provinces and many other subdivisions are planned and elucidated. A transitory idea about the dynamic forces which help make the Industry more prosperous are deliberated in order to help customer appreciate the future market situation. Projected revenue progression in terms of capacity with respect to the Global Gate Bipolar Transistors (IGBT) STATCOM market for the forthcoming years have been stated in-depth.

Top Key Players/Vendors:

Hitachi, CG, Schneider Electric, Mitsubishi Electric, Comsys AB, Ingeteam, Merus Power, Zhongke Tianlong Technology.

Regions Covered:

North America

Europe

China

Japan

Southeast Asia

India.

Get Up To 30% Discount @

https://www.researchnreports.com/ask_for_discount.php?id=144101

This research makes use of principal and subordinate sources to comprehensively cover the state of Gate Bipolar Transistors (IGBT) STATCOM Market. Industrialists, suppliers, contractors, traders, end-users and Industry specialists etc., were referred to authenticate the data of the research. Other information rounded up includes tendencies, difficulties and experiments, Industry drivers, market experience, policies and expansions of the industry. This information proved to have an influence on the growth of the Gate Bipolar Transistors (IGBT) STATCOM Market. All these factors are measured and examined in detail to come to a fair assumption.

Reasons for Buying this Report:

This report provides pin-point analysis for changing competitive dynamics.

It provides a forward looking perspective on different factors driving or restraining market growth.

It provides a six-year forecast assessed on the basis of how the Industry is predicted to grow.

It helps in understanding the key product segments and their future.

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors.

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of Industry segments.

It provides distinctive graphics and exemplified analysis of major Industry segments.

Analysts also reflected every factor that could be used to distinguish drivers, limitations, opportunities and threats of the Global Gate Bipolar Transistors (IGBT) STATCOM Market. Some of these influences include annual revenue, key segments, production capacity and new products. Industry principles are also documented for market analysis.

Any Query? Ask to our Expert@

https://www.researchnreports.com/enquiry_before_buying.php?id=144101

For the better understanding of the market, after incoming of the overall market size, the analyst were able to accurately split the Industry into numerous segments. The broken-down market research report functioned as a basis to recognize the movements of Global Gate Bipolar Transistors (IGBT) STATCOM Industry in the global scenario and double checked data is offered to support every argument. Hence, the analysts were able to arrive to an up-to-standard decision of the market activities and were able to deliver a fair report on the development forecast of the Global Gate Bipolar Transistors (IGBT) STATCOM Industry.

Another key note to be declared here is integration of market desirability index in the report particularizing growth, enactment and opportunities in the Gate Bipolar Transistors (IGBT) STATCOM Industry. The report is determined by enclosure of the competitive landscape among major players involved in production of the market components. The subdivision contains a far-reaching company summarizing and dashboard presentation of major players.

Browse the Complete Report on:

Global Gate Bipolar Transistors (IGBT) STATCOM Market Research Report 2017

Global Cartilage Repair Market to Grow at CAGR 11.59 %: Market Trends, Vendor Landscape, Growth Rate Analysis and Forecast 2017-2021

Cartilage Repair market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

Cartilage is a smooth elastic muscle, which covers the ends of the bone and serves as a bearing surface of the joint. Articular cartilage is produced by chondrocytes. Chondrocytes are the cells that divide and multiply very slowly as they do not have blood vessels. This is one of the reasons articular cartilage injuries do not repair well and can lead to continued degradation and deterioration of joint condition, leaving few treatment options available for the patients.

The treatment of articular cartilage has evolved tremendously in the past decade. Reparative and restorative methods have been developed to address the significant source of morbidity in the young and active patients. Articular cartilage injury can be focal, which is localized or systemic. Procedures are being developed not only to alleviate the symptoms associated with articular cartilage defects but also to limit the progression of cartilage damages into degenerative diseases.

Get a free sample of Cartilage Repair market report @ https://www.360marketupdates.com/enquiry/request-sample/11005690

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Cartilage Repair market projected to grow at a CAGR of 11.59% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: –

  • Gene therapy and stem cell therapy
  • Increasing partnerships and collaborations
  • Innovation and discovery of novel products

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005690

Market Segmentation: –

  • By product: –
  • Cell-based
  • Non-cell-based cartilage repair products
  • By end-user:-
  • Hospitals and clinics
  • ASCs
  • Physicians’ offices

Geographic Segmentation: –

  • Cartilage repair market in the Americas
  • Cartilage repair market in EMEA
  • Cartilage repair market in APAC

To calculate the Cartilage Repair market size the report considers the new sales/value of cartilage repair market. The report covers the market landscape and its growth prospects over the coming years.

Further it converses about key vendors operating in Cartilage Repair market like Acelity, DePuy Synthes, Stryker, Smith & Nephew, AlloSource, Bio-Tissue, CellGenix, Collagen Solutions, Geistlich Pharma, Orteq, RTI Surgical, TORNIER, Vericel, and XTANT MEDICAL.

Some of the Exhibits included in Cartilage Repair Market report: –

Exhibit 01: Global cartilage repair market: Overview

Exhibit 02: Global cartilage repair market: Impact assessment

Exhibit 03: Scope of cartilage repair market in various regions 2016-2021

Exhibit 04: Global cartilage repair market 2016-2021 ($ millions)

Exhibit 05: Focus for existing companies and end-users

Exhibit 06: Opportunity analysis of global cartilage repair market

Exhibit 07: Five forces analysis

Exhibit 08: Global cartilage repair market revenue by product in 2016-2021 ($ million)

Exhibit 09: Clinical study to prove the efficacy of chondrocyte transplantation

Exhibit 10: Market overview: Cell-based cartilage repair products

Exhibit 11: Global cell-based cartilage repair market 2016-2021 ($ millions)

Exhibit 12: Market overview: Non-cell based cartilage repair products

Exhibit 13: Global non-cell based cartilage repair market 2016-2021 ($ millions)

Purchase Cartilage Repair market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005690

With geographic breakdown of the market in terms of detailed analysis and impact, Cartilage Repair market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.

Global Photoelectric Sensors Market to Grow at CAGR 8.08 %: Strengths, Weaknesses of the Key Players Analysis and Forecast 2017-2021

Photoelectric Sensors market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

A photoelectric sensor is a special type of proximity sensor used to detect the distance, absence, and presence of any object in its predefined perimeter. These sensors sense and trigger to slow down or stop an operation for safety. A photoelectric sensor uses a beam of ray mostly infrared, and mainly consists of a transmitter and an emitter, either in two different devices and or in the same device.

Photoelectric sensors used in industrial applications are considered for market estimation and forecast. Photoelectric sensors used in automobiles, consumer durables, and vision guided mobile devices are not included in the report scope.

Get a free sample of Photoelectric Sensors market report @ https://www.360marketupdates.com/enquiry/request-sample/11005680

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Photoelectric Sensors market projected to grow at a CAGR of 8.08% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: –

  • Emergence of integrated smart sensors
  • Increasing use of collaborative robots
  • Implementing proximity sensors for automated warehouse safety

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005680

Market Segmentation: –

  • By technology: –
  • Global reflective photoelectric sensors market
  • Global through beam photoelectric sensors market
  • Global diffuse photoelectric sensors market
  • By end-user
  • Global photoelectric sensors market in process industries
  • Global photoelectric sensors market in discrete industries

Geographic Segmentation: –

  • Photoelectric sensors market in Americas
  • Photoelectric sensors market in EMEA
  • Photoelectric sensors market in APAC

To calculate the Photoelectric Sensors market size the report considers the new installations, retrofits and replacements. The report covers the market landscape and its growth prospects over the coming years.

Further it converses about key vendors operating in Photoelectric Sensors market like Banner, Baumer Group, OMRON, Pepperl+Fuchs, SICK, Balluff, Eaton, Fargo Controls, ifm, KEYENCE, Panasonic, Rockwell Automation, Schneider Electric, and Turck.

Some of the Exhibits included in Photoelectric Sensors Market report: –

Exhibit 01: Types of proximity sensors

Exhibit 02: Global photoelectric sensors market segmentation

Exhibit 03: Global photoelectric sensors market 2016-2021 ($ millions)

Exhibit 04: Applications of photoelectric sensors

Exhibit 05: Five forces analysis

Exhibit 06: Global photoelectric sensors market by technology 2016 and 2021 (% share)

Exhibit 07: Global reflective photoelectric sensors market 2016-2021 ($ millions)

Exhibit 08: Advantages and disadvantages of the reflective photoelectric sensors

Exhibit 09: Global through beam photoelectric sensors market 2016-2021 ($ millions)

Exhibit 10: Advantages and disadvantages of the through beam photoelectric sensors

Exhibit 11: Global diffuse photoelectric sensors market 2016-2021 ($ millions)

Exhibit 12: Advantages and disadvantages of the diffuse photoelectric sensors

Exhibit 13: Global photoelectric sensors market by end-users 2016 and 2021 (% share)

Purchase Photoelectric Sensors market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005680

With geographic breakdown of the market in terms of detailed analysis and impact, Photoelectric Sensors market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.

Business Insights on Azadirachtin Suspension Concentrate Market Global Industry trends made available by top research firm Forecast 2017-2022

“Global Azadirachtin Suspension Concentrate Market Research Report 2017”, Purchase This Report by calling ResearchnReports.com at +1-888-631-6977.

The study report titled Global Azadirachtin Suspension Concentrate Market offers an in-depth analysis of this market across the globe. The study, aimed at providing current and prospect players in this market sharp insights to gain the advantage over their competitors. The report does so by providing an executive summary including all valuable market figures and exploring the favorable factors that are expected to drive the growth rate of the market, besides taking account of the restraining factors. The report also highlights the emerging trends in the global market.

This statistical surveying report investigates and inspects the Azadirachtin Suspension Concentrate Market and determines a widely inclusive estimate of its development and its details. Another perspective that was efficient is the cost analysis of the prime products driving in the business remembering the overall revenue of the manufacturers.

Get PDF Sample of Azadirachtin Suspension Concentrate Market Report@

https://www.researchnreports.com/request_sample.php?id=149685

It clarifies a thorough synopsis of Global Azadirachtin Suspension Concentrate market dependent on the central parameters. End users, merchandises, provinces and many other subdivisions are planned and elucidated. A transitory idea about the dynamic forces which help make the Industry more prosperous are deliberated in order to help customer appreciate the future market situation. Projected revenue progression in terms of capacity with respect to the Global Azadirachtin Suspension Concentrate market for the forthcoming years have been stated in-depth.

Top Key Players/Vendors:

FMC, Novozyme, Nufarm, Sumitomo Chemical, Valent Biosciences, Adama Agricultural, Agrium, Arysta Lifescience.

Regions Covered:

North America

Europe

China

Japan

Southeast Asia

India.

Get Up To 30%  Discount @

https://www.researchnreports.com/ask_for_discount.php?id=149685

This research makes use of principal and subordinate sources to comprehensively cover the state of Azadirachtin Suspension Concentrate Market. Industrialists, suppliers, contractors, traders, end-users and Industry specialists etc., were referred to authenticate the data of the research. Other information rounded up includes tendencies, difficulties and experiments, Industry drivers, market experience, policies and expansions of the industry. This information proved to have an influence on the growth of the Azadirachtin Suspension Concentrate Industry. All these factors are measured and examined in detail to come to a fair assumption.

Reasons for Buying this Report:

This report provides pin-point analysis for changing competitive dynamics.

It provides a forward looking perspective on different factors driving or restraining market growth.

It provides a six-year forecast assessed on the basis of how the Industry is predicted to grow.

It helps in understanding the key product segments and their future.

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors.

It helps in making informed business decisions by having complete insights of Industry and by making in-depth analysis of Industry segments.

It provides distinctive graphics and exemplified analysis of major Industry segments.

Analysts also reflected every factor that could be used to distinguish drivers, limitations, opportunities and threats of the Global Azadirachtin Suspension Concentrate Market. Some of these influences include annual revenue, key segments, production capacity and new products. Industry principles are also documented for Industry analysis.

Any Query? Ask to our Expert@

https://www.researchnreports.com/enquiry_before_buying.php?id=149685

For the better understanding of the market, after incoming of the overall market size, the analyst were able to accurately split the Industry into numerous segments. The broken-down market research report functioned as a basis to recognize the movements of Global Azadirachtin Suspension Concentrate Industry in the Global scenario and double checked data is offered to support every argument. Hence, the analysts were able to arrive to an up-to-standard decision of the market activities and were able to deliver a fair report on the development forecast of the Global Azadirachtin Suspension Concentrate Industry.

This report is a full analysis which includes product type, applications, deployment, verticals, technology and regional segmentations. To gain a clear understanding of the breakdown of the Azadirachtin Suspension Concentrate market, the report also reviews the performance of it’s in the market scenario, power. The report provides statistics for each key segment of the global Azadirachtin Suspension Concentrate market in order to shed light on the development patterns exhibited by the market.

Browse the Complete Report on:

Global Azadirachtin Suspension Concentrate Market Research Report 2017

„Call for Papers” für AQR Insight Award 2018

GREENWICH, Connecticut–(BUSINESS WIRE)–AQR Capital Management, LLC („AQR“) nimmt ab heute Bewerbungsunterlagen für seinen siebten alljährlichen AQR Insight Award entgegen.

Der AQR Insight Award würdigt und honoriert außergewöhnliche wissenschaftliche Arbeiten, die in der Praxis anwendbar sind und originelle, intelligente Herangehensweisen zu Themen in der Anlagebranche vermitteln. Das alljährliche Preisgeld in Höhe von 100.000 US-Dollar wird auf drei Beiträge verteilt.

Die Gewinner werden vom AQR Insight Award Committee gewählt, einem Gremium aus hochrangigen Mitarbeitern des Unternehmens, von denen viele führende wissenschaftliche Finanzexperten aus Spitzenuniversitäten sind.

AQR nimmt Beiträge zu jedem investitionsbezogenen Thema an, in denen klare, wesentliche Einsichten vermittelt werden. Die Arbeiten dürfen nicht vor dem 1. Oktober 2017 veröffentlicht werden.

Abgabefrist für die Beiträge ist der 1. November 2017. Anschließend wird das Committee aus dem Kreis der Finalisten eine Vorauswahl von fünf Arbeiten treffen und die Verfasser dieser Arbeiten werden eingeladen, dem Committee in Greenwich, Connecticut, im Mai ihre Untersuchungen vorzustellen.

Zu den Empfängern des AQR Insight Award zählen zahlreiche angesehene Wissenschaftler. Frühere Gewinner des ersten Preises sind:

2017
„Deviations from Covered Interest Rate Parity“ von Wenxin Du, Ph.D., Federal Reserve Board, Alexander Tepper, Ph.D., Columbia University, und Adrien Verdelhan, Ph.D., MIT Sloan School of Management.

2016
A Tough Act to Follow: Contrast Effects in Financial Markets“ von Samuel M. Hartzmark, Ph.D., University of Chicago Booth School of Business, und Kelly Shue, Ph.D., University of Chicago Booth School of Business und NBER, sowie „Size Discovery“ von Darrell Duffie, Ph.D., Graduate School of Business, Stanford University, und Haoxiang Zhu, Ph.D., MIT Sloan School of Management.

2015
Commodity Trade and the Carry Trade: A Tale of Two Countries“ von Robert Ready, Ph.D., Simon School of Business, University of Rochester, Nikolai Roussanov, Ph.D., Wharton School, University of Pennsylvania und NBER, und Colin Ward, Ph.D., Carlson School of Management, University of Minnesota, sowie „Option-Based Credit Spreads“ von Christopher L. Culp, Ph.D., Johns Hopkins University und Swiss Finance Institute, Yoshio Nozawa, Ph.D., Federal Reserve Board, und Pietro Veronesi, Ph.D., University of Chicago Booth School of Business, NBER und CEPR.

2014
The High-Frequency Trading Arms Race: Frequent Batch Auctions as a Market Design Response“ von Eric Budish, Ph.D., University of Chicago, Peter Cramton, Ph.D., University of Maryland, College Park, und John J. Shim, University of Chicago.

2013
Conditional Risk Premia in Currency Markets and Other Asset Classes“ von Martin Lettau, Ph.D., University of California in Berkeley, Matteo Maggiori, Ph.D., New York University, und Michael Weber, University of California in Berkeley.

2012
Market Expectations in the Cross Section of Present Values“ von Bryan Kelly, Ph.D., University of Chicago Booth School of Business, und Seth Pruitt, Ph.D., Federal Reserve Board of Governors.

Weitere Informationen und eine Anleitung für Online-Bewerbungen finden Sie unter www.aqr.com/insightaward.

Über AQR

AQR ist eine globale Vermögensverwaltungsgesellschaft im Schnittpunkt zwischen Finanztheorie und praktischer Anwendung. Wir sind bestrebt, qualitativ hochwertige und langfristige Ergebnisse für unsere Kunden zu erzielen, indem Störfaktoren analysiert werden und identifiziert und präzisiert wird, welche die signifikantesten Faktoren sind, und indem Methoden entwickelt werden, die strengen Überprüfungen standhalten. Unsere Konzentration auf praktische Informationen und Analysen hat dazu beigetragen, dass unser Unternehmen seit 1998 ein führender Anbieter im Bereich alternativer und traditioneller Strategien ist.

Das in Greenwich im US-Bundesstaat Connecticut ansässige Unternehmen unterhält Niederlassungen in Boston, Chicago, Los Angeles, London, Hongkong und Sydney. Zum 30. Juni 2017 verwaltete AQR ein Vermögen von rund 195 Milliarden US-Dollar.*

*Enthält Vermögen von AQR und seinen Beratungsgesellschaften

Diese Pressemitteilung dient lediglich zu Informationszwecken. Sie stellt weder ein Angebot noch eine Aufforderung zur Abgabe eines Angebots, noch einen Rat oder eine Empfehlung, zum Kauf von Wertpapieren oder Finanzinstrumenten dar und sollte nicht als solche ausgelegt werden oder als Grundlage für eine Investitionsentscheidung dienen.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Global Bio-surfactants Market to Grow at CAGR 6.02 %: Decision Framework, Drivers, Challenges Analysis and Forecast 2017-2021

Bio-surfactants market report provides actionable intelligence on major factors influencing the market (drivers, opportunities, industry specific challenges, and other critical issues) along with the market size of various segments.

Bio-surfactants are amphiphilic compounds that are produced on the surfaces of living organisms (mostly microorganisms) or discharged extracellularly. They have both hydrophobic and hydrophilic parts, which makes them capable of reducing the surface tension between two liquid surfaces or a liquid and a solid surface. They can aggregate different interfaces of media with varying polarities. Apart from this, they also function as foaming agents, detergents, wetting agents, and emulsifiers. These functions make bio-surfactants a vital component in several industries such as agriculture, pharmaceutical, chemical cleaning, textile, food, and preservatives. They are biodegradable; with less toxicity; and effective in high temperature, pH, and salinity.

Get a free sample of Bio-surfactants market report @ https://www.360marketupdates.com/enquiry/request-sample/11005689

On the grounds of comprehensive, reliable data derived from extensive research of multiple sources (both primary and secondary) and in-depth market analysis with inputs from industry experts, Bio-surfactants market projected to grow at a CAGR of 6.02% during the period 2017-2021.

Drivers and Challenges: –

  • Market drivers
  • Market challenges

Market trend: –

  • Potential use of marine origin bio-surfactant for cancer treatment
  • Use of recombinant DNA technology for improved production of bio-surfactant
  • Use of rhamnolipids for cleaning diesel particulate filter

Have a query? Ask about it @ https://www.360marketupdates.com/enquiry/pre-order-enquiry/11005689

Market Segmentation: –

  • By application :-
  • Global bio-surfactant market for detergent and fabric softener sector
  • Global bio-surfactant market for cosmetics and personal care sector
  • Global bio-surfactant market for industrial and institutional cleaners sector
  • Global bio-surfactant market for food processing sector
  • Global bio-surfactant market for oilfield chemical sector
  • Global bio-surfactant market for agriculture sector
  • Global bio-surfactant market for textile sector
  • Global bio-surfactant market for pharmaceutical sector
  • Global bio-surfactant market for other sectors
  • By product: –
  • Global bio-surfactants market by methyl ester sulfonate
  • Global bio-surfactants market by alkyl polyglucoside
  • Global bio-surfactants market by sorbitan ester
  • Global bio-surfactants market by sucrose ester
  • Global bio-surfactants market by rhamnolipid
  • Global bio-surfactants market by other product types

Geographic Segmentation: –

  • Bio-surfactant market in Europe
  • Bio-surfactant market in North America
  • Bio-surfactant market in APAC
  • Bio-surfactant market in ROW

To calculate the Bio-surfactants market size the report considers the retail selling price is considered as the average selling price of the product. The report covers the market landscape and its growth prospects over the coming years.Further it converses about key vendors operating in Bio-surfactants market like Akzo Nobel, BASF, Croda International, Ecover, Saraya, AGAE Technologies, Clariant, Evonik, GlycoSurf, Jeneil Biotech, Kemin Industries, Logos Technologies, SEPPIC, Stepan, and TensioGreen.

Some of the Exhibits included in Bio-surfactants Market report: –

Exhibit 01: Types of bio-surfactant and micro-organisms that produce them

Exhibit 02: !by product

Exhibit 03: !by application

Exhibit 04: Global bio-surfactant market 2016 and 2021 ($ millions)

Exhibit 05: Forecast: Global bio-surfactant market 2016-2021

Exhibit 06: Five forces analysis

Exhibit 07: Global bio-surfactant by application 2016

Exhibit 08: Global bio-surfactant by application 2021

Exhibit 09: Global bio-surfactant market for detergent and fabric softener sector 2016 and 2021 ($ millions)

Exhibit 10: Forecast: Global bio-surfactant market for detergent and fabric softener sector 2016-2021

Exhibit 11: Global bio-surfactant market for cosmetics and personal care 2016 and 2021 ($ millions)

Exhibit 12: Forecast: Global bio-surfactant market for cosmetics and personal care sector 2016-2021

Exhibit 13: Global bio-surfactant market for industrial and institutional cleaners sector 2016 and 2021 ($ millions)

Purchase Bio-surfactants market research report at $ 3500(Single User Licence) @ https://www.360marketupdates.com/purchase/11005689

With geographic breakdown of the market in terms of detailed analysis and impact, Bio-surfactants market report analyses business dimensions with an eye on individual growth trends and contribution of upcoming market segments.